Previous close | 147.37 |
Open | 150.11 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 146.93 - 147.40 |
52-week range | 146.93 - 147.40 |
Volume | |
Avg. volume | N/A |
Market cap | 2.191B |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 0.21 |
EPS (TTM) | 6.97 |
Earnings date | 26 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2024.
AbbVie (NYSE: ABBV) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib (RINVOQ®, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (DUPIXENT®, per its labeled dose) in adults and adolescents (≥12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of th
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BO